With compelling Phase 2 data in both ulcerative colis("UC") and rheumatoid arthritis ("RA") ABX464 looks well positioned as a potential broad range anti-inflammatory. Oral and safe ABX464 appears has efficacy on par and better sustained than competing drugs. Phase 2b UC data shows 58% of patients in clinical remission after 48 months of maintenance therapy. Phase 2a rheumatoid arthritis ("RA") data achieved the primary safety and tolerability endpoint and statistically significant improvement in ....
17 Nov 2021
Transformative safe effective oral anti-inflammatory
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Transformative safe effective oral anti-inflammatory
With compelling Phase 2 data in both ulcerative colis("UC") and rheumatoid arthritis ("RA") ABX464 looks well positioned as a potential broad range anti-inflammatory. Oral and safe ABX464 appears has efficacy on par and better sustained than competing drugs. Phase 2b UC data shows 58% of patients in clinical remission after 48 months of maintenance therapy. Phase 2a rheumatoid arthritis ("RA") data achieved the primary safety and tolerability endpoint and statistically significant improvement in ....